HOUSTON, Oct. 17, 2019 /PRNewswire/ -- Researchers
from Invitae Corporation (NYSE: NVTA), a leading medical
genetics company, are presenting data showing the increasing
utility of genetic information at the American Society of Human
Genetics (ASHG) annual meeting this week, ranging from
comprehensive screening for cancer patients, to appropriate
clinical follow up for women using non-invasive prenatal screening,
to the limitations of direct to consumer genetic screening health
reports.
The company's research includes three platform presentations and
multiple poster sessions, many performed in collaboration with
leading academic researchers. Among the data presented is a study
evaluating the utility of combined germline testing and tumor
profiling (somatic testing) in cancer patients. Germline and
somatic testing are increasingly used in precision treatment of
people with cancer, although frequently are ordered separately in
clinical practice. Data presented at the meeting shows a
substantial number of patients with medically significant variants
in hereditary cancer syndrome genes in their tumor profile carry
the same variant in their germline, thereby establishing a
previously unknown risk of hereditary cancer and suggesting the
value of combined or concurrent testing to inform precision
medicine approaches.
"The research we are presenting at this year's ASHG meeting
provides meaningful insight into both the science and practice of
genetics, helping identify how we as clinicians can better use deep
genetic insights to help a wide array of patients, whether they are
cancer patients, women having a child or healthy adults seeking to
better understand their risk of disease," said Robert Nussbaum, M.D., chief medical officer of
Invitae. "We are proud and grateful to be able to join our
colleagues from across genetic medicine in meaningful conversations
that push genetic medicine forward."
Following are research from the company and collaborators to be
presented at the meeting:
Wednesday, October
16:
Poster presentation #819W | 2:00 – 3:00
pm
Germline testing in colorectal cancer: Increased yield and
precision therapy implications of comprehensive multigene panels.
Presented by Shan Yang, PhD.
Invitae.
Poster presentation #2427W | 2:00 – 3:00
pm
Harmonizing tumor sequencing with germline genetic testing:
identification of at-risk individuals for hereditary cancer
disorders. Presented by Daniel
Pineda-Alvarez, MD, FACMG, Invitae.
Poster presentation #606W | 3:00 – 4:00
pm
A comprehensive evaluation of the importance of prenatal diagnostic
testing in the era of increased utilization of non-invasive
prenatal screening. Presented by Jenna
Guiltinan, MS, LCGC, Invitae.
Thursday, October
17:
Platform presentation #235 | 5:00
pm, Room 370A, Level 3
Limitations of direct-to-consumer genetic screening for hereditary
breast, ovarian and colorectal cancer risk. Presented by:
Edward Esplin, MD, PhD, FACMG, FACP,
Invitae.
Poster presentation #763T | 2:00 – 3:00
pm
In-depth dissection of APC pathogenic variants: Spectrum of more
than 400 pathogenic variants, challenges of variant interpretation,
and new observations in a large clinical laboratory testing cohort.
Presented by: Hio Chung Kang, PhD,
Invitae.
Poster presentation #1399T | 2:00 – 3:00
pm
Prediction of lethality and severity of osteogenesis imperfecta
variants in the triple-helix regions of COL1A1 and COL1A2.
Presented by: Vikas Pejaver, PhD,
University of Washington.
Friday, October
18:
Platform presentation #264 | 9:00
am, Room 361D, Level 3
Million Veteran Program Return Of Actionable Results - Familial
Hypercholesterolemia (MVP-ROAR-FH) Study: Considerations for
variant return to mega-biobank participants. Presented by
Jason Vassy, MD, MPH, VA, Boston
Healthcare System.
Platform presentation #265 | 9:15
am, Room 361D, Level 3
Comprehensive secondary findings analysis of parental samples
submitted for exome evaluation yields a high positive rate.
Presented by Eden Haverfield, DPhil,
FACMG, Invitae.
Poster presentation #698F | 2:00 – 3:00
pm
Reporting of variants in genes with limited, disputed, or no
evidence for a Mendelian condition among GenomeConnect
participants. Presented by: Juliann
Savatt, MS, LGC, Geisinger.
About Invitae
Invitae Corporation (NYSE:
NVTA) is a leading medical genetics company, whose mission is
to bring comprehensive genetic information into mainstream medicine
to improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time, and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the increasing utility of genetic information; the
utility of combined germline and somatic testing; and the benefits
of the company's research. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially, and reported results should not be considered as
an indication of future performance. These risks and uncertainties
include, but are not limited to: the applicability of clinical
results to actual outcomes; the company's history of losses; the
company's ability to compete; the company's failure to manage
growth effectively; the company's need to scale its infrastructure
in advance of demand for its tests and to increase demand for its
tests; the company's ability to use rapidly changing genetic data
to interpret test results accurately and consistently; security
breaches, loss of data and other disruptions; laws and regulations
applicable to the company's business; and the other risks set forth
in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. These forward-looking statements
speak only as of the date hereof, and Invitae Corporation disclaims
any obligation to update these forward-looking statements.
Contact:
Laura D'Angelo
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:http://www.prnewswire.com/news-releases/research-presented-by-invitae-at-the-american-society-of-human-genetics-meeting-pushes-science-and-practice-of-genetics-forward-300940213.html
SOURCE Invitae Corporation